Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04528511
Recruiting Observational

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction

NCT04528511 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai 10th People's Hospital
Phase
Observational
Started
2020-10-01
Last updated
2026-03-19

Condition(s) studied

Atrial Fibrillation New OnsetAcute Myocardial Infarction

Investigational drug(s) / intervention(s)

Continuous Electronic Monitor

Continuous Electronic Monitor: All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden

Study summary

To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (\>18 years old); * Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization; * Patients must have received in-hospital CEM for at least 5 days; * Patients must give informed consent. Exclusion Criteria: * Patients with a medical history of pre-existing AF; * Patients with a medical history of rheumatic valvular disease; * Patients with a medical history of sick sinus syndrome; * Patients undergoing emergent coronary artery bypass surgery; * Patients who suffer malignant tumors with an expected lifetime less than 1 year ; * Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved; * Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI; * Patients who have died during the index hospitalization.

Primary outcome measure(s)

  • All-cause death — up to 1 year
    Death from any cause

Trial sites (5)

FacilityCityRegionStatus
Kaifeng Central Hospital Kaifeng Henan Recruiting
Luoyang Central Hospital Luoyang Henan Recruiting
The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan Recruiting
Department of Cardiology, Shanghai Tenth People's Hospital Shanghai Shanghai Municipality Recruiting
Shanghai Seventh People's Hospital Shanghai Shanghai Municipality Recruiting

More Shanghai 10th People's Hospital trials in China

Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Recruiting
Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study Active, not recruiting
Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia Recruiting
An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection Starting soon
Treatment of Perioperative Neurocognitive Disorders With Olfactory Enrichment Recruiting

Other trials for the same condition

Effect of Digital Therapeutics for Cardiac Rehabilitation in Patients With Acute Myocardial Infarction Starting soon
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury Recruiting
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction Recruiting
Survival and cArdiovascular eVents in Patients With Acute Myocardial Infarction Recruiting
Prospective Acute Myocardial Infarction Data Bank Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04528511 on ClinicalTrials.gov ↗ ← All trials in China